Resistance, New Antibiotics, and Continued Fun with Fungus –
What the Oncology Pharmacist Needs to Know (Recorded HOPA Insights eSeries presented on 6/10/15)
This HOPA Insights eSeries presentation will review current data supporting concepts in the antibacterial/antifungal prophylaxis and treatment of immunocompromised patients with a focus on hematologic malignancy.
- Describe the need for new antibiotics and the problems with developing them
- Recognize the strengths and limitations of emerging antibacterials
- Identify the differences between colistin and polymyxin b
- List the clinically important differences in advanced generation azole antifungals
- Identify the roles of echinocandins and advanced generation azoles in 2015
James S. Lewis II, PharmD, FIDSA
ID Clinical Pharmacy Coordinator
Departments of Pharmacy and Infectious Diseases
Oregon Health and Science University
Disclosure: The faculty and planners do not have anything to disclose.
This activity is intended for Hematology/oncology pharmacists.
This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-15-042-H04-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. A statement of credit will be issued only upon completion of the post-activity evaluation form and post-test. Individuals who attended the live broadcast of “Resistance, New Antibiotics, and Continued Fun with Fungus – What the Oncology Pharmacist Needs to Know” on June 10, 2015 and claimed live CE credit are ineligible to claim credit for completing this online activity.
View Webinar Free Here
To Claim Credit
If you would like to claim credit for the on demand webinar participants must:
(1) read the learning objectives and faculty disclosures
(2) view the recording
(3) purchase the online post-test by clicking here
(4) Follow the instructions on your email receipt to access the post-test;
(5) complete the online post-test and evaluation prior to printing out the certificate of completion.
Release Date: July 14, 2015
Expiration Date: June 10, 2018
To receive credit, Purchase Now >
Disclosure of Conflicts of Interest
The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict
Planners and Managers
Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data.
The faculty and planners do not have anything to disclose.
Unlabeled/Unapproved Uses of Drugs
All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.